Perfil
Dr. Chris Wahl is a Chief Scientific Officer at Halozyme Therapeutics, Inc. Dr. Wahl was previously employed as a Vice President-Strategy & Business Development by Biora Therapeutics, Inc., a Chief Operating Officer by Interface Therapeutics, Inc., and a Chief Operating Officer by Micropharma Ltd. He received his undergraduate degree from Lee University, an MBA from McGill University and a doctorate degree from McGill University.
Cargos activos de Chris Wahl
| Empresas | Cargo | Inicio |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Director Técnico/Científico/I+D | - |
Antiguos cargos conocidos de Chris Wahl.
| Empresas | Cargo | Fin |
|---|---|---|
| BIORA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Interface Therapeutics, Inc. | Fundador | - |
Micropharma Ltd.
Micropharma Ltd. Pharmaceuticals: MajorHealth Technology Formulates, manufactures & sells functional food, neutraceuticals and pharmaceutical products | Director de Operaciones | - |
Formación de Chris Wahl.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 6 |
|---|---|
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
Micropharma Ltd.
Micropharma Ltd. Pharmaceuticals: MajorHealth Technology Formulates, manufactures & sells functional food, neutraceuticals and pharmaceutical products | Health Technology |
McGill University
McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lee University
Lee University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biora Therapeutics, Inc.
Biora Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company focused on developing targeted therapies for cancer and autoimmune diseases | Health Technology |
Interface Therapeutics, Inc. |
- Bolsa de valores
- Insiders
- Chris Wahl
















